Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

University of California

Paul A Luciw

Dino Dina

Deborah Lynn Parkes

Philip J Barr

Carlos George-Nascimento

Martha Truett

Kathelyn S Steimer

Rob Hallewell

Ray Sanchez Pescador

Steven Rosenberg

Gary Van Nest

Nancy L Haigwood

Richard M Thayer

Barbara S Chapman

Gary A Van Nest

Luis D Giavedoni

Tilahun D Yilma

Ellen E Sparger

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

Human immunodeficiency virus (HIV) nucleotide sequences

Purified pol DNA, a recombinant DNA construct for expression of HIV pol polypeptide sequences and a cell containing such construct

Method for expressing HIV polypeptides

Recombinant DNA construct for HIV envelope polypeptides and polypeptides produced thereby

Recombinant DNA constructs for GAG polypeptides and polypeptides produced thereby

Antigenic composition comprising an HIV gag or env polypeptide

HIV immunoassays using synthetic envelope polypeptides

Human immunodeficiency virus (HIV) nucleotide sequences, recombinant polypeptides, and applications thereof

Methods for detecting human immunodeficiency virus nucleic acid

HIV immunoassays using gag polypeptides

This invention discloses recombinant vectors and live attenuated pathogens produced by these vectors which are useful as vaccines and therapeutic agents. Particularly disclosed are live attenuated recombinant viruses that remain at very low virus loads, and preferably do not persist in the infected hosts. These recombinant viruses are useful against retroviruses such as human immunodeficiency virus and against acquired immunodeficiency diseases. In the recombinant vectors and pathogens, one or more genes, or part of the gene(s), responsible for pathogenesis have been completely or partially rendered nonfunctional, e.g., by full or partial deletion or mutagenesis. Further, the recombinant vectors and pathogens contain one or more genes encoding cytokine(s) and/or lymphokine(s).

Attenuated lentivirus vectors expressing interferon

Immunoassay of HIV antibodies using recombinant or synthetic selected

This invention discloses live-attenuated feline immunodeficiency virus (FIV), and recombinant vectors for producing them, useful as vaccines and therapeutic agents against FIV and diseases associated with virulent FIV infection. In the recombinant vectors and FIVs, one or more genes, or part of the gene(s), responsible for FIV pathogenesis have been completely or partially rendered nonfunctional, e.g., by full or partial deletion or mutagenesis. These anti-FIV vaccines may be given to susceptible hosts in the form of infectious virus or cloned DNA.

Recombinant live feline immunodeficiency virus and proviral DNA vaccines

Vector for expression of a polypeptide in a mammalian cell

Growing community of inventors

Davis, CA, United States of America

Paul A Luciw